September 2026
The celiac disease treatment market was valued at USD 879.06 million in 2026, with leading companies including Takeda Pharmaceutical Company Limited, Amgen Inc.
September 2026
The global fabry disease treatment market size reached USD 2.65 billion in 2026 and is estimated to hit around USD 5.20 billion by 2035 with a CAGR of 7.82%.
September 2026
The rare diseases treatment market size was estimated at USD 266.68 billion in 2026and is predicted to hit around USD 566.83 billion by 2035 with a CAGR of 8.77%.
September 2026
The global sickle cell disease treatment market size is predicted to hit around USD 15.81 billion by 2035 from USD 4.35 billion in 2026 with a CAGR of 15.48%.
September 2026
The global inflammatory bowel disease treatment market size is projected to hit around USD 32.46 billion by 2035 from USD 22.38 billion in 2025, with a CAGR of 3.79%.
September 2026
The global periodontal disease treatment market size was evaluated at USD 3.17 billion in 2026 and is predicted to hit around USD 6.23 billion by 2035, growing at a CAGR of 7.80%.
December 2025
The chronic obstructive pulmonary disease treatment market size is expected to hit around USD 33.03 billion by 2035 from USD 21.04 billion in 2025 at a CAGR of 5.14%.
July 2025
The global hearing loss disease treatment market reached USD 14.43 billion in 2024 and is projected to surpass around USD 24.03 billion by 2034 with a CAGR of 5.23%.
June 2025
The global peripheral arterial disease treatment market size is estimated to hit around USD 6.11 billion by 2034 from USD 3.41 billion in 2026, with a CAGR of 7.56%.
September 2026
The orphan disease biomarkers market expands with advancements in genomics, proteomics, and bioinformatics for rare conditions.
September 2026
The rare disease small-batch CDMO market is expanding with demand for specialized manufacturing of orphan drugs and niche therapies.
September 2026
The U.S. point of care infectious disease testing market size is projected to hit around USD 5.27 billion by 2035, growing at a CAGR of 8.98% from 2026 to 2035.
September 2026
The global infectious disease diagnostics market size is expected to reach around USD 71.06 billion by 2035 from USD 37.98 billion in 2026 with a CAGR of 7.22%.
September 2026
The infectious disease therapeutics market size is calculated at USD 37.67 billion in 2026 and is expected to hit around USD 53.48 billion by 2035 at a CAGR of 3.97%.
September 2026
The global point-of-care infectious disease diagnostics market size is projected to hit around USD 25.66 billion by 2035, with a CAGR of 15.26% from 2026 to 2035.
September 2026
The global respiratory disease vaccine market size was calculated at USD 103.17 billion in 2026 and is projected to hit around USD 123.77 billion by 2035 with a CAGR of 2.04%.
September 2026
The infectious disease in-vitro diagnostics market size is valued at USD 28.78 billion in 2026 and is expected to hit around USD 35.68 billion by 2035, growing at a CAGR of 2.42%.
September 2026
The end stage renal disease market was valued at USD 174.43 billion in 2026, with end stage renal disease market leading companies including Nipro Corp., Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc.,Medtronic Plc.
September 2026
The global disease management apps market size is calculated at USD 10.20 billion in 2026 and is projected to hit around USD 27 billion by 2035 with a CAGR of 10.22%.
September 2026
The global graves disease (overactive thyroid) market size is estimated to hit around USD 3.69 billion by 2035 increasing from USD 2.37 billion in 2026, with a CAGR of 5.02%.
September 2026
The infectious respiratory disease diagnostics market size was USD 60.62 billion in 2026, with leading infectious respiratory disease diagnostics market players including F. Hoffmann - La Roche, Thermo Fisher Scientific, Danaher (Cepheid), Abbott LaboratoriesÂ
September 2026
The global sexually transmitted diseases diagnostics market size is estimated to hit around USD 21.44 billion by 2034 from USD 12.26 billion in 2026, with a CAGR of 7.24%.
September 2026
The global enteric disease testing market size was evaluated at USD 4.58 billion in 2026 and is predicted to hit around USD 8.09 billion by 2035, growing at a CAGR of 6.52%.
September 2026
The global inflammatory disease market size was evaluated at USD 133.50 billion in 2026 and is predicted to hit around USD 241.34 billion by 2035, growing at a CAGR of 6.80%.
September 2026
The parkinsons disease biomarkers market size reached USD 1.54 billion in 2026, with leading parkinsons disease biomarkers market companies including F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Thermo Fisher Scientific, Abbott Laboratories.
September 2026
The global Alzheimers disease diagnostics market size was evaluated at USD 10.42 billion in 2026 and is predicted to hit around USD 26.21 billion by 2035, growing at a CAGR of 10.80%.
September 2026
The global Huntingtons disease market size was evaluated at USD 1.66 billion in 2026 and is predicted to hit around USD 6.48 billion by 2035, growing at a CAGR of 17.20%.
June 2026
The global non-alcoholic fatty liver disease (NAFLD) drug market size is estimated to hit around USD 35.10 billion by 2035 from USD 23.04 billion in 2026, with a CAGR of 4.79%.
June 2026
The global minimal residual disease (MRD) testing market size is estimated to hit around USD 5.19 billion by 2035; billion by 2035 increasing from USD 1.91 billion in 2026, with a CAGR of 11.81%.
September 2026
The infectious disease immunoassay market size stood at USD 3.22 billion in 2026, with major infectious disease immunoassay market companies including Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux SA, Siemens Healthineers AG, Beckman Coulter, Inc.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com